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E-mail address: ijs.ubc@gmail.com (I. Sadowski).Latent HIV-1 (human immunodeﬁciency virus-1) provirus is unaffected by current AIDS (acquired
immunodeﬁciency syndrome) therapies. We show here that chaetocin, an SUV39H1 histone meth-
yltransferase inhibitor, causes 25-fold induction of latent HIV-1 expression, while producing mini-
mal toxicity and without causing T cell activation. Induction is associated with loss of histone H3
lysine 9 (H3K9) trimethylation at the long terminal repeat (LTR) promoter, and a corresponding
increase in H3K9 acetylation. The effect of chaetocin is ampliﬁed synergistically in combination with
histone deacetylase (HDAC) inhibitors. These results indicate that chaetocin may provide a therapy
to purge cells of latent HIV-1, possibly in combination with other chromatin remodeling drugs.
Crown Copyright  2011 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. All rights reserved.1. Introduction
AIDS (acquired immunodeﬁciency syndrome) has become a
manageable disease since the introduction of highly active anti-
retroviral therapy (HAART), which can suppress HIV loads to unde-
tectable levels. During infection, a population of latently infected
cells becomes established in unstimulated CD4+ T-helper cells,
which are not affected by HAART [1]. Unfortunately, the latently
infected population decays very slowly (t1/2 = 6–44 months), mak-
ing eradication of infection improbable [2]. A variety of strategies
have been considered to force expression of latent HIV with the
objective of ‘‘purging’’ this otherwise impenetrable infection [3],
which include the use of histone deacetylase (HDAC) inhibitors
to cause remodeling of nucleosomes at the LTR and force increased
expression [4–7]. This approach shows some promise [6,7], but
because latent HIV genomes are silenced by mechanismsd by Elsevier B.V. on behalf of Fede
rus-1; H3K9, histone 3 lysine
lide hydroxamic acid; TSA,
drome; HAART, highly active
Biochemistry and Molecular
th Sciences Mall, Vancouver,associated with heterochromatin [8,9], it is unlikely that HDAC
inhibitors alone will be capable of purging the entire population
of latently infected cells.
Methylation at histone H3 lysine 9 (H3K9) is associated with
repressive heterochromatin, which must be removed to allow tran-
scription [10]. This can be encouraged by treatment with histone
methyltransferase inhibitors. For example, the fungal metabolite
chaetocin is an inhibitor of the lysine-speciﬁc histone methyltrans-
ferase SUV39H1 [11]. This compound was recently shown to have
anti-cancer activities related to its ability to cause re-expression of
tumor suppressor genes [12]. These ﬁndings prompted us to
investigate whether chaetocin could also cause reactivation of
latent HIV-1 (human immunodeﬁciency virus-1).
2. Materials and methods
2.1. Recombinant DNA molecules
The pTY-LAI-luc HIV-1 LTR mini-virus reporter was produced
from the lentiviral vector pTY-EFeGFP (NIH AIDS Reagent
Program). The luciferase ORF was cloned into the NsiI/SwaI sites,
and a wild type 30 LTR fragment, generated by PCR from the HIV-1
pLAI clone with oligos oMD027 (AAAGAATTCTTTAAGACCAATGAC
TTACAAGGC) and oTM0238 (GGGGTACCCCCT TTATTGAGGCTTAration of European Biochemical society. All rights reserved.
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Fig. 1. Chaetocin activates an integrated HIV-1 minivirus. (A) Schematic representation of the pTY-LAI-luc reporter virus. (B) Jurkat cells with the integrated minivirus were
left untreated (0 h) or stimulated with chaetocin at the indicated concentrations, and luciferase activity was measured after 4, 8, 12 or 24 h. (C) Cells were stimulated with
chaetocin at the indicated concentrations; luciferase activity (fold induction) and % cell death were measured.
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Fig. 2. Chaetocin affects histone modiﬁcation and transcription factor binding on the HIV-1 LTR. Cells were left untreated or induced with 100 nM chaetocin for 8 h. ChIP was
performed with anti-trimethyl-H3K9 (Panel A), anti-acetylated H3K9 (Panel B), anti-p65 NFjB (Panel C) or anti-TBP (Panel D). Error bars represent the standard deviation,
⁄ represents P values <0.05, ⁄⁄ represents P values <0.005 and ⁄⁄⁄ represents P values <0.0005.
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(Fig. 1A). pGL3-Basic and pGL3-HIV-1were used for transient trans-
fections [13].
2.2. Cell lines, transfections and cell culture
VSV pseudotyped pTY-LAI-luc virus was produced by co-trans-
fection of Human embryonic kidney (HEK) 293T cells (ATCC) as
previously described [14]. Infected Jurkat-tat (NIH-AIDS) cells were
monitored for eGFP expression and clones isolated by FACS. Jurkat
cells were transiently transfected using an Amaxa Nucleofector
(Lonza). For luciferase assays, cells were plated at 1  106 cells/
mL, and induced with PMA (Sigma), chaetocin (Sigma) and/or
SAHA (suberoylanilide hydroxamic acid) (Toronto Res. Chemicals)
for the indicated times. Reporter expression was determined using
the Bright-Glo System (Promega). Cell viability was determined by
staining with Hoechst (0.5 lg/mL), and propidium iodide (PI,
0.25 lg/mL) in 96 well plates. After 30 min at 37 C the plates werescanned in a CellomicsTM Arrayscan ﬂuorescence imager; Hoechst
and TRITC channels were used to determine total cell numbers
and PI positive (dead) cells, respectively. To determine CD69
expression, cells were ﬁrst blocked with 2.4G2 antibody, and then
stained on ice for 30 min with 5 lL of anti-human CD69 antibody
conjugated to R-phycoerythrin (PE) or PE conjugated mouse IgG1
isotype control antibody (BD Biosciences). The cells were then
washed and stained with 25 ng/mL 40,6-diamidino-2-phenylindole
(DAPI) to distinguish live cells before analysis on an BD Biosciences
ﬂow cytometer. Data were analyzed using FlowJo analysis software
(Tree Star). To measure IL-2 production, culture supernatants were
collected and assayed by ELISA using a human IL-2 ELISA System
(eBioscience).
2.3. ChIP assays
Cells were induced with 500 nM PMA or 100 nM chaetocin, and
crosslinked with 1% formaldehyde for 10 min at room temperature.
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Fig. 3. Chaetocin does not cause activation of T-cells. Cells were induced with PMA, chaetocin and SAHA for 4 h. (A) IL-2 expression in the supernatant was determined. (B)
Cell surface expression of CD69 was measured with CD69 antibodies and FLOW cytometry. (C) Photographs were taken after 2 and 4 h treatment.
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ing to the suppliers instructions, and assayed by qPCR using oligos
speciﬁc for the HIV-1 LTR core promoter (P1: AGTGGCGAGCCCTC-
AGAT, and P2: AGAGCTCCCAGGCTCAAATC). Results for NFjB p65
and TBP are normalized to controls using oligos speciﬁc for GAPDH
[14], and for reactions with anti-H3K9trimethylation and acetyla-
tion to controls for total histone H3.
3. Results
3.1. Chaetocin activates the HIV-1 LTR in Jurkat T cells
To examine whether chaetocin was capable of causing activa-
tion of latent HIV-1, we used a Jurkat T-cell line bearing an inte-
grated HIV-1 minivirus where luciferase is produced from the 50
LTR as an in-frame fusion with p24gag (Fig. 1A). We observed some
induction as early as 4 h post-treatment, and a peak induction of
25-fold at 8 h was sustained for up to 12 h treatment over a con-
centration range of 12–100 nM (Fig. 1B). Importantly, at this con-
centration, we observed minimal cell toxicity as measured by PI
staining, and chaetocin does not have a signiﬁcant effect on viabil-
ity at concentrations as high as 100 nM (Fig. 1C).
3.2. Activation of the HIV-1 LTR by chaetocin is accompanied by loss of
H3K9 tri-methylation and increased binding of TBP, but not NFjB
To examine whether induction of the LTR by chaetocin involves
chromatin modiﬁcation, we used chromatin immunopreciptiation
(ChIP) to examine modiﬁcation of histone H3K9. We found that
the ratio of trimethylation at H3K9, relative to total histone H3,
was decreased by 70% in cells that were induced with chaetocin
for 8 h (Fig. 2A). In contrast, histones associated with the LTR in
unstimulated cells are hypoacetylated, but acetylation at H3K9
increases by 90% after 8 h treatment (Fig. 2B). The ﬁnding that
chaetocin decreases H3K9 trimethylation, which is accompaniedby an increase in acetylation, suggests that this compound causes
reorganization of chromatin at the LTR.
The activator NFjB plays a signiﬁcant role in induction of genes
downstream of the T-cell receptor (TCR) [15]. In T cells, PMA
causes translocation of NFjB into the nucleus where it binds
TCR-responsive gene promoters, including the LTR in HIV-1
infected cells [15]. Consequently, we wondered whether NFjB is
involved in induction of the LTR in chaetocin-treated cells. Using
ChIP, we found that the amount of NFjB present on the LTR
increased by 70% in cells treated with PMA, but NFjB p65 did
not become associated with the LTR in cells treated with chaetocin
(Fig. 2C). In contrast to NFjB p65, we did observe recruitment of
TATA-binding protein (TBP) to the LTR in cells treated with either
chaetocin or PMA (Fig. 2D). TBP as part of TFIID binds to the
TATA-box, and is required for assembly of the general transcription
factors (GTFs) at the core HIV-1 promoter [16]. These results indi-
cate that chaetocin must produce an environment on the LTR
which allows recruitment of the GTFs and activation of transcrip-
tion by mechanism(s) that bypass stimulation of NFjB. This is
consistent with the ﬁnding that chaetocin causes loss of H3K9
tri-methylation and accumulation of H3K9 acetylation, indicating
signiﬁcant chromatin remodeling at the LTR.
3.3. Chaetocin does not cause activation of Jurkat T-cells
One problem with potential therapies pursuing the goal of
activating latent virus is that general T-cell activation produces
cytotoxic effects [17]. Activated T-cells secrete cytokines such as
IL-2, which plays a pivotal role in immune response. T-cell activa-
tion is also characterized by increased surface expression of CD69
which acts in T-cell proliferation and signaling [18], and accord-
ingly we observe induction of IL-2 and CD69 in Jurkat cells treated
with PMA (Fig. 3A and B). In contrast, treatment of cells with chae-
tocin for 8 h did not cause a change in CD69 or IL-2 expression,
indicating that chaetocin is capable of inducing HIV-1 expression
3552 W. Bernhard et al. / FEBS Letters 585 (2011) 3549–3554without causing global T-cell activation. Activated T-cells undergo
a variety of morphological changes including decreased aggrega-
tion and adherence to the substratum [18]. This was observed in
Jurkat cells treated with PMA, where after 2 h treatment the cells
become dispersed, ﬂatten out and attach to the plate (Fig. 3C).
However, we do not observe these effects in cells treated with
chaetocin (Fig. 3C).
3.4. Chaetocin acts synergistically with TSA and SAHA
Because chaetocin seems to activate HIV-1 expression by a
mechanism involving chromatin remodeling, we examined
whether it produced synergistic effects with other chromatin
remodeling drugs. Histone acetylation is a marker of active chro-
matin and is increased on the activated HIV LTR [8,9] (Fig. 2B).
The HDAC inhibitors TSA (trichostatin A) and SAHA were shown
to cause some induction of integrated HIV-1 LTRs [9], and consis-
tent with this we found that TSA on its own increased expression
from the pTY-LAI-luc minivirus by only 10-fold at a concentration
of 130 nM (Fig. 4A). The effect of TSA was signiﬁcantly enhanced in
combination with 50 and 100 nM chaetocin, where we observe
40- and 90-fold induction, respectively (Fig. 4A). Similarly, SAHA
on its own caused 14-fold induction at a concentration of 25 lM,
but this effect is signiﬁcantly enhanced by chaetocin, such thatC
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tion with 6.25 lM of SAHA (Fig. 4B). Importantly, chaetocin in
combination with the HDAC inhibitors caused minimal toxicity at
concentrations that produce peak induction (Fig. 4C and D). Higher
concentrations of SAHA of 100 lM causes 20% cell death, but this
effect is not exaggerated by chaetocin (Fig. 4D). Induction by chae-
tocin in combination with TSA and SAHA appears to be synergistic,
as 100 nM chaetocin in combination with 0.5 lM TSA or 6.25 lM
SAHA produces 80-fold induction, whereas these compounds alone
cause less than 20-fold stimulation (Fig. 4E and F).3.5. Chaetocin causes a slower and weaker response of transient LTR
templates
In contrast to the above results, we found that an HIV-1 LTR
reporter gene introduced into Jurkat T-cells by transient transfec-
tion was induced more slowly and to less signiﬁcant levels, such
that we only observe 2-fold induction after 72 h treatment
(Fig. 5). It is well documented that transiently transfected reporters
do not become properly assembled into chromatin [19], and conse-
quently this result supports the view that chaetocin causes activa-
tion of the LTR by mechanism(s) which promote formation of
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In this study we show that chaetocin, an inhibitor of SUV39H1,
causes induction of an integrated HIV-1 mini-virus. The effect is
observed within 8 h post-treatment, occurs without producing glo-
bal T-cell activation, and produces a synergistic effect on HIV-1
expression in combination with HDAC inhibitors. Induction is
accompanied by loss of tri-methylation at H3K9 and a correspond-
ing increase in H3K9 acetylation. These results are similar to a pre-
vious study that shows chaetocin is capable of reactivating
epigenetically silenced tumor suppressor genes through inhibition
of SUV39H1 to produce a decrease in H3K9 tri-methylation [12].
We also note that a previous study did not observe a signiﬁcant ef-
fect of chaetocin on latent HIV-1 [20], but we believe the difference
in our experiments is that peak induction occurs after 8 h, and is
lost by 24 h (Fig. 1B), whereas in contrast this previous study only
examined expression after 16 h. Additionally, an shRNA directed
against SUV39H1 caused only small induction of the LTR within a
comparable time frame [20].
T-cells normally become activated by T-cell receptor engage-
ment during antigen presentation [18]. This can be mimicked using
agonists such as PMA, which stimulates T-cell responses including
enhanced cell adhesion and increased expression of IL-2 and CD69
[18]. Cells stimulated with chaetocin and/or the HDAC inhibitor
SAHA do not exhibit these phenotypes.. Stimulation of Jurkat cells
with PMA causes activation of the HIV-1 LTR through NFjB [21].
Consistent with the ﬁnding that chaetocin does not cause global
T-cell activation, we ﬁnd that NFjB p65 does not bind the LTR in
chaetocin-treated cells. Chaetocin was shown to cause oxidative
stress in myeloma cells [22], and importantly oxidative stress of
Jurkat cells induces expression of HIV-1, apparently through acti-
vation of NFjB [23]. Because we do not observe an effect of chae-
tocin on association of NFjB p65 with the LTR, it is possible that
this compound does not produce a comparable stress response in
the Jurkat cell line. TSA and SAHA were also shown to stimulate
HIV-1 expression without NFjB activation [5,6]. The HIV-1 LTR is
bound by numerous sequence-speciﬁc transcription factors
in vitro that are present in unstimulated T-cells [24]. It is well
established that latent HIV-1 provirus is produced by repressive
chromatin, which would normally preclude activation by these fac-
tors [8,9]. Consequently, we propose that chaetocin initiates exten-
sive remodeling of chromatin at the LTR promoter to produce an
environment that is permissive for binding of multiple activators.
Effective treatment regimes typically involve combinations of
drugs because of synergy, where lower concentrations can be used
to decrease side effects. We show here that chaetocin producessynergistic effects on HIV-1 expression in combination with the
HDAC inhibitors TSA and SAHA. Several other histone methyltrans-
ferase inhibitors, including BIX1294 speciﬁc for G9a, and the
broad-spectrum inhibitor DZNep, were also shown to act synergis-
tically with SAHA to induce HIV-1 [20,25]. Also, SUV39H1 shRNA
was shown to cause a small increase of HIV-1 expression, and this
effect was activated synergistically with shRNA directed against
the EZH2 methyltransferase [20]. These studies, in combination
with the results shown here, support a view that combinations of
histone methyltransferase inhibitors, including chaetocin, and
HDAC inhibitors may represent potential safe and effective thera-
pies for purging latent HIV-1 reservoirs.
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